Summary
Definition
History and exam
Key diagnostic factors
- age 10-19 or 30-39 years
- motor weakness
- paresthesias or sensory loss
- bladder symptoms: urinary frequency, urgency, incontinence, or retention
- bowel symptoms: incontinence or constipation
- L'hermitte sign
- McArdle sign
- paroxysmal tonic spasms
- upper motor neuron signs: hyperreflexia, positive Babinski sign, limb spasticity
- sensory loss/sensory level
- dyspnea/respiratory distress
Other diagnostic factors
- back pain
- trunk/limb pain
- areflexia/hyporeflexia
- hiccups
- nausea/vomiting
Risk factors
- preceding infectious illness
- recent vaccination
- female sex
- history of recent physical trauma
- spinal injection
Diagnostic investigations
1st investigations to order
- MRI spinal cord
- MRI brain
- serum aquaporin-4 autoantibodies and myelin oligodendrocyte glycoprotein autoantibodies
- cerebrospinal fluid cell count, cell differential, protein level, IgG index, oligoclonal bands
- cerebrospinal fluid Gram stain, cultures (bacterial, tubercular, fungal), and India ink smear
- cerebrospinal fluid, polymerase chain reaction for herpes simplex virus (HSV)-1, HSV-2, varicella zoster virus (VZV), Borrelia burgdorferi (Lyme disease), cytomegalovirus (CMV), Epstein-Barr virus (EBV), and West Nile virus
- cerebrospinal fluid Venereal Disease Research Laboratory test
- serum anti-nuclear antibody, double-stranded DNA
- extractable nuclear antigen (including SSA and SSB autoantibodies)
- serum and cerebrospinal fluid paraneoplastic autoantibodies
- other neural autoantibodies
Investigations to consider
- serum and cerebrospinal fluid angiotensin-converting enzyme
- CXR
- CT body (chest, abdomen, and pelvis)
- whole-body PET scan
- cerebrospinal fluid cytology and flow cytometry
- serology for herpes simplex virus (HSV)-1, HSV-2, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, and West Nile virus
- urinalysis
- HIV antibodies
- visual-evoked potential
- optical coherence tomography
- therapeutic trial with corticosteroid
- spinal cord biopsy
Treatment algorithm
acute neurologic deficits
idiopathic transverse myelitis (TM)
at risk for multiple sclerosis (MS) (typical demyelinating lesions on MRI)
aquaporin-4 (AQP4) autoantibody seropositive
myelin oligodendrocyte glycoprotein-IgG autoantibody seropositive
Contributors
Authors
Cristina Valencia-Sanchez, MD, PhD
Department of Neurology
Mayo Clinic
Scottsdale
AZ
Disclosures
CVS declares that she has served on an advisory board for TG Therapeutics.
Acknowledgements
Dr Cristina Valencia-Sanchez would like to gratefully acknowledge Dr Dean Wingerchuk, the previous contributor to this topic. DMW has received compensation from MedImmune for service on a clinical trial adjudication committee, from Caladrius for consulting services, and research support paid to Mayo Clinic from Alexion and TerumoBCT. DMW is an author of a number of references cited in this topic.
Peer reviewers
Alireza Minagar, MD
Assistant Professor of Neurology
LSU Health Sciences Center
Shreveport
LA
Disclosures
AM declares that he has no competing interests.
Cory Toth, BSc, MD, FRCP(C)
Assistant Professor of Neurosciences
Hotchkiss Brain Institute
University of Calgary
Alberta
Canada
Disclosures
CT declares that he has no competing interests.
Abhijit Chaudhuri, DM, MD, PhD, FACP, FRCP
Consultant Neurologist
Clinical Director of Neurosciences
Department of Neurology
Queen's Hospital
Romford
UK
Divulgaciones
AC declares that he has no competing interests.
Agradecimiento de los revisores por pares
Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.
Divulgaciones
Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.
Referencias
Artículos principales
Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002 Aug 27;59(4):499-505. Resumen
Expert Panel on Neurological Imaging, Agarwal V, Shah LM, et al. ACR appropriateness criteria® myelopathy: 2021 update. J Am Coll Radiol. 2021 May;18(5s):S73-82.Texto completo Resumen
Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018 Apr 24;90(17):777-88.Texto completo Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
Diferenciales
- Compressive myelopathy
- Infectious myelitis (e.g., tuberculosis)
- Anterior spinal artery occlusion
Más DiferencialesGuías de práctica clínica
- ACR appropriateness criteria: myelopathy
- Practice guideline: disease modifying therapies in adults with multiple sclerosis
Más Guías de práctica clínicaFolletos para el paciente
Multiple sclerosis
Más Folletos para el pacienteInicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad